




# PHARMACEUTICAL 2021

Orgenesis Inc.  
Rank 355 of 402





RealRate

# PHARMACEUTICAL 2021

Orgenesis Inc.  
Rank 355 of 402



The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Orgenesis Inc. is the variable Net Income, reducing the Economic Capital Ratio by 249% points.

The company's Economic Capital Ratio, given in the ranking table, is -198%, being 246% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	50,077
Cost of Goods Sold	0
Intangible Assets	21,768
Liabilities, Current	16,285
Liabilities, Non-Current	8,671
Other Assets	2,766
Other Compr. Net Income	-1,066
Other Expenses	2,087
Other Liabilities	0
Other Net Income	-94,539
Other Revenues	7,656
Property and Equipment	3,073
Research and Development	83,986
Selling, General and Administrative Expense	18,973

Output Variable	Value in 1000 USD
Assets	77,684
Liabilities	24,956
Expenses	105,046
Revenues	7,656
Stockholders Equity	52,728
Net Income	-191,929
Comprehensive Net Income	-192,462
Economic Capital Ratio	-198%